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Edited by Gianni CesareniAbstract A mammalian baculovirus delivery system was devel-
oped to study targeting in Norden Laboratories feline kidney
(NLFK) cells of the capsid proteins of canine parvovirus
(CPV), VP1 and VP2, or corresponding counterparts fused to
EGFP. VP1 and VP2, when expressed alone, both had equal nu-
clear and cytoplasmic distribution. However, assembled form of
VP2 had a predominantly cytoplasmic localization. When VP1
and VP2 were simultaneously present in cells, their nuclear local-
ization increased. Thus, confocal immunoﬂuorescence analysis of
cells transduced with the diﬀerent baculovirus constructs or com-
binations thereof in the absence or presence of infecting CPV re-
vealed that the VP1 protein is a prerequisite for eﬃcient
targeting of VP2 to the nucleus. The baculovirus vectors were
functional and the genes of interest eﬃciently introduced to this
CPV susceptible mammalian cell line. Thus, we show evidence
that the system could be utilized to study targeting of the CPV
capsid proteins.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Structurally and genetically related to feline panleukopenia
virus and mink enteritis virus [1,2], canine parvovirus (CPV)
is a type member of autonomous Parvovirus genus [3]. Non-
enveloped capsids of CPV are assembled from 60 copies of
the viral protein (VP) structural proteins [4]. The virion of
CPV has a diameter of approximately 25 nm. It has a T = 1
icosahedral symmetry. An eight-stranded anti-parallel beta
barrel motif is found in the CPV capsid, like in most viral cap-
sid structures [4–6]. The linear single-stranded DNA genome
(5 kb) contains two promoters directing the expression of
two non-structural proteins (NS1 and NS2) in the left reading
frame, or for the structural proteins (VP1 and VP2) in the right
reading frame [1,7]. Full DNA-containing capsids are predom-
inantly composed of a combination of VP2 and VP3 proteins,*Corresponding authors. Fax: +358 14 260 2221 (L. Gilbert,
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VP2, VP1 has additional 143 N-terminal amino acid residues
and VP3 is proteolytically cleaved from VP2 by the removal
of about 12–15 amino acids from the N-terminus of VP2
[3,9]. Empty capsids form similar amounts as in full capsids
in CPV infected cells and have a composition of VP1 and
VP2 only in a ratio of 1:10. Previously, it has been shown that
VP2 can assemble into capsid-like structures.
The steps of a CPV infection are only partially characterized.
The location of host range determinants has been mapped to
the surface of the capsid structure [5,10]. It has been reported
that CPV and feline parvovirus (FPV) bind to human and fe-
line transferrin receptors, TfRs [11]. CPV enters the cells by a
dynamin-dependent, clathrin-mediated endocytic pathway
where the capsids ﬁnally co-localize with the TfR in perinu-
clear vesicles [12,13]. One of the last compartments in the
CPV entry route has been identiﬁed as lysosomes [14]. Once
in the cell, capsids penetrate only slowly into the cytoplasm.
It has been shown that when anti-capsid antibodies were in-
jected into the cytoplasm even at 6 h after virus inoculation,
productive infection was prevented [15]. These results suggest
that capsids can remain within the endocytic compartments
several hours after uptake. In addition, a potential nuclear
localization signal of SV40-type has been identiﬁed within
the N-terminal part of VP1 [16]. Further, some speciﬁc changes
in the identiﬁed NLS reduced the relative infectivity of the
CPV capsids [17]. In the case of minute virus of mice
(MVM), both VP1 and VP2 have NL sequences. Two classical
NL sequences were mapped near the VP1 speciﬁc N-terminus,
while a sequence in VP2, rich in basic amino acids, has been
shown to be associated with nuclear transport in a conforma-
tion-dependent manner [18,19].
Baculoviridae is a family of large enveloped arthropod viruses
that contain large circular double-stranded DNA genomes and
baculoviruses have a restricted host range limited to few closely
related species within a single genus or family [20–23]. A proto-
type virus of this family is Autographa californica M nucleo-
polyhedrovirus (AcMNPV) [24] and AcMNPV is commonly
used in the baculovirus expression vector system (BEVS).
The BEVS has been used to produce a variety of parvovirus-
speciﬁc proteins. Among these, virus-like particles (VLPs) have
been produced for adeno-associated virus [25], Aleutian mink
disease parvovirus [26], muscovy duck parvovirus [27], human
parvovirus B19, porcine parvovirus [28–30], and canine parvo-
virus [31–35]. Recently, baculoviral vectors have also been
used to eﬃciently mediate gene transfer and expression in
various mammalian cell lines both in vitro [36–45] and in vivoblished by Elsevier B.V. All rights reserved.
Fig. 1. Schematic picture of the baculovirus constructs. PCR products
were digested with appropriate restriction enzymes (italic) and
transferred to pFastbacI. Genetic constructs had the polyhedrin
promoter (SnaBI and BamHI) replaced with the cytomegalovirus-
immediate early promoter (CMV) (NruI and BamHI). Nucleotides of
the fusion protein junction (bold), EcoRI site (underlined), and
corresponding amino acids (bold) are outlined.
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used. Improvements in gene transfer and speciﬁc targeting to
mammalian cells by this system have also been conducted
[45,50–52]. Furthermore, it has been shown that baculoviruses
are unable to replicate in mammalian cells and little or no
cytotoxicity is detected in the context of baculovirus transduc-
tion [36,53]. An in vitro system for studying hepatitis B virus
replication [54–56] as well as a system to determine replication
competence of virus transcripts [57,58] have been established
using recombinant baculovirus transduction of mammalian
cells. Besides cell lines, an in vivo system was used to transfer
the hemagglutinin gene of the inﬂuenza virus [59]. In addition,
it has been shown that recombinant baculovirus can be used in
monitoring long-term ex vivo and in vivo expression of trans-
duced viral genes without perturbing the physiological state of
the transduced cell [60].
In the present study, we have examined the role of using re-
combinant baculovirus as tools to study intracellular localiza-
tions of the CPV VP1 protein with respect to nuclear targeting
of its viral structural counterpart VP2. This was carried out by
constructing various recombinant baculovirus housing VP1
and VP2 with or without the enhanced green ﬂuorescent pro-
tein (EGFP) as a tag. These baculoviral constructs were used
to transduce NLFK cells by employing the cytomegalovirus
immediate–early (CMV-IE) promoter. Together, we have
established a novel and gentle system for introduction of parv-
oviral proteins and genes into mammalian cells to investigate
the nuclear targeting of VP1 and VP2 of CPV.2. Materials and methods
2.1. Genetic baculovirus constructs
VP1 of CPV was ampliﬁed by PCR using p265 (Collin Parrish, Cor-
nell University, Ithaca, NY) as a template with the sense oligonucleo-
tide primer 5 0-TA CAT GGA TCC ATG GCA CCT CCG-3 0 (BamHI
site and start codon underlined) and the antisense oligonucleotide pri-
mer 5 0-CGA GGC GAA TTC TTA ATA TAA TTT TCT AGG TGC-
3 0 (EcoRI site and stop codon underlined). VP2 cloning with a stop
codon followed similar procedures as described previously [31]. For
C-terminal fusion of VP1 and VP2 to EGFP, the antisense oligonu-
cleotide primer without a stop codon was 5 0-CCG A GGC GAA
TTC ATA TAA TTT TCT AGG TG C-3 0 (EcoRI site underlined).
PCR products of VP1 and VP2 (with or without a stop codon) were
cloned into the corresponding restriction sites of pFastBacI (Gibco-
BRL, Grand Island, NY). The resulting plasmids with the stop codons
were named pVP1Fastbac pVP2Fastbac and without the stop codons
pVP1woFastbac and pVP2woFastbac, respectively.
For C-terminal fusion of VP1 and VP2, the sequence encoding
EGFP was ampliﬁed using pEGFP-C1 (Clontech, Palo Alto, CA).
The oligonucleotide primers for EGFP were 5 0-GTC GAA TTC
ATG GTG AGC AAG GGC GAG GAG-3 0 (sense, EcoRI site and
translational start codon underlined) and 5 0-TCT TCT AGA TTA
CTT GTA CAG CTC GTC CAT GCC-3 0 (antisense, XbaI site and
stop codon underlined). PCR products of EGFP were digested with
EcoRI and XbaI and cloned into the corresponding restriction sites
of pVP1woFastbac, pVP2woFastbac, and pFastbacI (Gibco-BRL).
Resulting plasmids without the VP1 or VP2 stop codons were desig-
nated pVP1EGFPFastbac, pVP2EGFPFastbac, and pEGFPFastbac.
All plasmid constructs were further digested with SnaBI and BamHI
to remove the polyhedrin promoter, which was replaced with the NruI
and BamHI fragment from plasmid pEGFP-C1 containing the CMV-
IE promoter. The ﬁnal constructs were named pCMVVP1Fastbac,
pCMVVP2Fastbac, pCMVVP1EGFPFastbac, pCMVVP2EGFPFast-
bac, and pCMVEGFPFastbac. The recombinant baculoviruses
AcCMVVP1, AcCMVVP2, AcCMVVP1EGFP, AcCMVVP2EGFP,
and AcCMVEGFP (Fig. 1) were generated using the Bac-to-Bac (Gib-
co-BRL) system and ampliﬁed by established procedures.2.2. Transduction of mammalian cells
Approximately 1 · 106 NLFK cells/ml were grown overnight on cov-
erslips at +37 C. Next day, growth medium was replaced with a mix-
ture of 30 ll DMEM–FCS and 30 ll of virus inoculum (AcCMVVP1,
AcCMVVP2, AcCMVVP1EGFP, AcCMVVP2EGFP, AcCMVEGFP
and AcCMVEGFPVP2 or combinations thereof), containing 1 · 108
plaque forming units (PFUs) per ml for each coverslip. After incuba-
tion (30 min, 37 C), 5 ml DMEM was added to the coverslips. Cells
were incubated (+37 C, 48 h), ﬁxed (100% methanol, 6 min, 20
C) and left in PBS at +4 C until immunostaining. Infection of bacu-
lovirus-transduced NLFK cells, initially transduced (24 h) with Ac-
CMVVP2EGFP, was followed by infection with wild-type CPV [61].
Wild-type CPV infected cells served as controls. At 48 h post transduc-
tion (24 h post-infection), cells were ﬁxed as above.
2.3. Immunostaining of cells
Primary antibodies used for probing proteins were a polyclonal rab-
bit anti-VP1 antibody, speciﬁc for the unique N-terminal sequence of
VP1 [62], polyclonal rabbit anti-VP antibody that recognizes all forms
of CPV viral proteins (from Collin Parrish), mouse monoclonal anti-
capsid antibody [63,64], and monoclonal mouse anti-non-structural
protein 1 (anti-NS1, from Collin Parrish). Secondary antibodies used
were alexa-633 (violet) conjugated anti-rabbit antibody and alexa-
546 (red) conjugated anti-mouse antibody (Molecular Probes, Eugene,
OR). Cells were permeabilized and immunostained and examined with
a laser scanning ﬂuorescence microscope (LSM 510, Zeiss) as described
[31].3. Results
Subcellular targeting of the structural proteins of CPV dur-
ing an authentic infection of NLFK cells is shown in Fig. 2.
The proteins were identiﬁed using a battery of antibodies spe-
ciﬁc for VP1 (anti-VP1; [62]), all forms of VP1 and VP2 (anti-
VP; from Collin Parrish), or assembled VP2 (anti-capsid;
[63,64]). As can be seen, both VP1 (Fig. 2(a) and (d)) and
assembled forms of VP2 (Fig. 2(b), (e) and (h), (k)) were tar-
geted to the nucleus even though they were also present in
the cytosol. On the contrary, antibodies recognizing all forms
of both proteins detected antigens quite evenly throughout the
infected cell (Fig. 2(g) and (j)). The diﬀerential interference
contrast (DIC; Fig. 2(c) and (i)) and merged (Fig. 2(f) and
(l)) images are shown. The roles of VP1 and VP2 in nuclear
Fig. 2. Confocal imaging of the subcellular distribution of structural
proteins (VP1 and VP2) in NLFK cells infected with CPV. Cells grown
on coverslips were infected for 24 h and stained with anti-VP1, anti-
VP, and anti-capsid antibodies. A clear nuclear as well as cytosolic
distribution is shown for VP1 (a) and capsids (b and h) in the CPV
infected cells. When probed with anti-VP (g), cytosolic and nuclear
localization is seen. An outline of the nucleus and colocalization is
shown in the DIC (c and i) and merged images (f and l). Confocal
images are 0.7 lm thick midsections of the cell in the same ﬁeld. Bars
10 lm. Phenotype quantitation of the corresponding confocal images
is also shown (d, e, j and k). Cells were classiﬁed in three categories
according to the distribution of label (immunostaining or direct
viewing of EGFP ﬂuorescence): predominantly nuclear (white bar),
comparable nuclear and cytoplasmic labeling (grey bar), and mainly
cytoplasmic labeling (black bar). The number of scored cells showing
protein synthesis is an average percentage of two independent
experiments (n > 150).
Fig. 3. Confocal imaging of NLFK cells transduced with AcCMVVP1
(a–f) and AcCMVEGFP (g–l). VP1 was detected with anti-VP1
antibody (a), whereas EGFP was viewed directly (h). Diﬀerential
interference contrast (DIC; c and i) as well as merged images (f and l)
are shown. Same planes of the cells were viewed and the images
represent single confocal midsections of approximately 0.7 lm in
thickness. Bars 10 lm. Subcellular distribution (graphs) of VP1 (d) and
EGFP (k) in the same transduced cells as well as negative controls (b, e
and g, j) is shown. Average percentage from the transduced cells
(n > 150) was determined from two independent experiments. Classi-
ﬁcations of the cells were used as in Fig. 2.
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lovirus delivery system as described below.
3.1. Individual expression and subcellular targeting of VP1 in
baculovirus-transduced NLFK cells
Recombinant baculoviruses housing the individual struc-
tural proteins, VP1 and VP2, as well as EGFP and its fusion
to VP2 were engineered for mammalian expression (Fig. 1).
The subcellular distribution of the individual protein con-
structs in NLFK cells transduced with the corresponding
viruses was studied by confocal imaging (Figs. 3–6) using the
battery of CPV speciﬁc antibodies presented above as well as
by direct viewing of EGFP ﬂuorescence. In addition, the distri-
bution of the ﬂuorescence was quantiﬁed using an amount of
150–200 cells in each case. Immunostaining of cells transducedwith the recombinant baculovirus, AcCMVVP1, revealed both
nuclear and cytoplasmic localization of the VP1 protein (Fig.
3(a) and (d)). The VP1-speciﬁc antibody used here did not bind
to cells transduced with the VP1-negative control virus, Ac-
CMVEGFP (Fig. 3(g) and (j)). In these cells, EGFP was dis-
tributed quite evenly throughout the cell (Fig. 3(h) and (k)).
The nuclei were identiﬁed by DIC (Fig. 3(c) and (i)) and the
merged images of the corresponding images are also outlined
(Fig. 3(f) and (l)).
3.2. Individual expression and subcellular targeting of VP2 in
baculovirus-transduced NLFK cells
Subcellular targeting of the VP2 proteins in NLFK cells
transduced with AcCMVVP2 and AcCMVVP2EGFP is por-
trayed in Fig. 4. Immunostaining of unassembled VP2 or
VP2EGFP proteins detected with anti-VP antibodies showed
an equal cytosolic and nuclear presence (Fig. 4(a), (e) and
(i), (m)). When stained for assembled VP2, a predominantly
cytoplasmic location was revealed with little staining observa-
ble in the nucleus (Fig. 4(b), (f) and (j), (n)). As compared to
the nuclear accumulation distribution of EGFP (Fig. 3(h)
and (k)), the ﬂuorescent chimeric version of VP2, VP2EGFP,
was found to be in discrete large areas in the cytoplasm when
analyzed by direct viewing (Fig. 4(k) and (o)). Similarly, the
Fig. 4. Confocal images of NLFK cells transduced with AcCMVVP2 (a–h) and AcCMVVP2EGFP (i–p) showing diverse subcellular distribution of
the VP2 protein probed with anti-VP or anti-capsid antibodies. The anti-VP antibody, detecting all forms of the CPV structural proteins, is seen
throughout the cells expressing VP2 and VP2EGFP (a and i). Mostly cytosolic localization is seen with the anti-capsid antibody detecting assembled
capsids or capsid-like structures (b and j). VP2EGFP, when viewed directly (k), shows mainly a cytosolic distribution. DIC (d and l) and merged (h
and p) images show the outline of the nuclei and colocalization, respectively. Confocal images are midsections of 0.7 lm in thickness of the same
planes for all cells. Bars 10 lm. The subcellular distribution of VP2 (e), VP2EGFP (m) and capsids (f and n) in the transduced cells is shown as an
average percentage (n > 150) from two independent experiments. Cells were classiﬁed into three categories as described in Fig. 2.
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when expressed alone suggesting that the ﬂuorescent fusion
partner, EGFP (Fig. 4), did not aﬀect the intracellular localiza-
tion of VP2. The DIC (Fig. 4(d) and (i)) and merged (Fig. 4(h)
and (p)) images are shown.
Together, these results show that the viral vectors were func-
tional and that VP1 displays a pronounced nuclear targeting
capacity. However when expressed alone, unassembled VP2
appeared to be distributed quite evenly throughout the cell,
whereas it appeared to retain in the cytosol if assembled.
3.3. Co-expression of VP1 and VP2 and consecutive subcellular
targeting of VP2
To elucidate the interaction of the VP1 and VP2 proteins,
NLFK cells were co-transduced with the recombinant bacul-
oviruses AcCMVVP1and AcCMVVP2 (Fig. 5). Cells stained
for VP1 showed an increase, targeting of the protein to the nu-
cleus (Fig. 5(a) and (d)) as compared to when expressed alone
(Fig. 3(a) and (d)). Interestingly, the anti-capsid antibody
showed a shift of stained antigens from the cytosol (Fig. 4(b)
and (f)) to the nuclear compartment (Fig. 5(b), (e) and (h),
(k)). Similarly, an increase in nuclear targeting was seen when
cells were probed using antibodies directed against all forms of
both structural proteins (Fig. 5(g) and (j)) as compared to VP2
seen in Fig. 4(a) and (e). Again, the nuclei were identiﬁed by
DIC (Fig. 5(c) and (i)). The merged images are also outlined
(Fig. 5(f) and (l)). These results clearly suggest that the trans-
port of the viral proteins into the nucleus is enhanced by the
presence of both.3.4. CPV infection of NLFK cells expressing the VP2EGFP
fusion protein
To verify the results described above, we carried out an
experiment where NLFK cells transduced with a baculovirus
construct harboring the VP2EGFP fusion were further in-
fected with authentic CPV at 24 h post transduction (Fig. 6).
Replication of CPV was conﬁrmed using an antibody directed
against the non-structural protein, NS1 (Fig. 6(b) and (f)). In
the infected cells, where VP1 is produced due to the CPV infec-
tion, the ﬂuorescent VP2EGFP fusion protein was clearly ob-
served both in the cytosol and the nucleus, but with a
pronounced nuclear targeting (Fig. 6(c), (g) and (k), (o)) when
viewing EGFP. In contrast, the VP2EGFP protein was found
predominantly in the cytosol in the absence of a CPV infection
as shown above (Fig. 4(k) and (o)). Here, the cellular distribu-
tion of the CPV structural proteins is further shown using anti-
VP (Fig. 6(a) and (e)), anti-VP1 (Fig. 6(i) and (m)), and the
anti-capsid antibodies (Fig. 6(j) and (n)). This result suggests
that at least VP1 is a prerequisite for targeting of VP2 into
the nucleus and that there could be other components of a
CPV infection that aid in this.4. Discussion
Determinants of nuclear targeting of the VP1 and VP2 struc-
tural proteins of CPV expressed in NLFK cells were sought by
using recombinant baculoviruses as genetic vectors. Here, the
structural proteins were expressed under various conditions
Fig. 5. Confocal images of NLFK cells co-transduced with
AcCMVVP1 and AcCMVVP2. Detection of proteins with anti-VP1
or anti-capsid antibodies displays more nuclear targeting as well as
equal nuclear and cytosolic distribution of VP1 (a) and capsid-like
structures (b and h). When probed for all viral proteins with anti-VP
(g), cytosolic and nuclear localization is seen with slight nuclear
targeting. Outlines of the nuclei and colocalization can be seen in the
DIC (c and i) and merged images (f and l), respectively. Confocal
images are 0.7 lm thick midsections of the cells in the same ﬁeld. Bars
10 lm. The subcellular distribution of VP1 (d), capsid-like structures
(b and h) and both viral proteins (j and k) is shown as an average
percentage (n > 200) from two independent experiments. Cells were
classiﬁed into three categories as described in Fig. 2.
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examined by direct viewing of EGFP and by using antibodies
staining for the VP1 speciﬁc region, all viral proteins, capsids,
or by direct viewing of EGFP ﬂuorescence [65].
Due to a slower transduction eﬃciency of baculovirus to
transduce NLFK as compared to wt CPV (data not shown),
infection of wild-type CPV at 24 h (Figs. 2 and 6) and trans-
duction for 48 h (Figs. 3–5) were compared. Similarly, experi-
ments with a combination of the structural proteins with or
without a wt infection were conducted to reach near physiolog-
ical states of the viral proteins (Fig. 5).
In cells infected with wild-type parvovirus, VP1 and VP2
must be transported to the nucleus after synthesis [19,66] to al-
low progeny virus to form. Our inspection of wild-type CPV
infected cells at 24 h showed nuclear accumulation of VP1,
capsids and unassembled VPs (Fig. 2). However, despite a high
sequestering of proteins in the nucleus, all the viral capsid pro-
teins studied were also found in the cytosol as also shown for
CPV and other parvoviruses by other investigators
[8,18,19,25,67–70].
Baculoviruses used for individual expression of VP1 (Fig. 3)
aided in the analysis of the cellular distribution of this struc-tural protein without other CPV viral components present.
Antigens for VP1 were seen to have both a cytosolic and a nu-
clear distribution (Fig. 3). As VP1 has shown to possess a po-
tential nuclear localization signal [16], targeting of this protein
to nucleus (Figs. 2b and 3a, b; [8,19]) was expected. However,
our ﬁndings that VP1 did not have a predominant nuclear
accumulation are in contrast to other studies where wild-type
infectious clones (MVM) were used [19]. The fact that singly
expressed VP1 without other viral proteins did not accumulate
as eﬃciently as in wild-type CPV (Fig. 2) suggests that the nu-
clear localization signal for VP1 is not the only requirement for
this protein to have high accumulation in the nucleus. It is sig-
niﬁcant that in our study VP1 at 48 h did accumulate in the nu-
cleus more eﬃciently when VP2 was present (see below, Figs. 5
and 6).
Nuclear translocation signals of VP2 of CPV have not been
characterized. Previously, it was shown [8] that plasmid-ex-
pressed VP2 mutants incapable of assembly into VLPs were
targeted to the nucleus as well as the cytosol in A72 cells. This
feature of unassembled VP2 to be in the cytosol and nucleus
has been seen with VP2 of other parvoviruses (MVM; [19],
AAV; [25,69]). In our study, VP2 probed with anti-VP was
found both in the cytosol and nucleus (Fig. 4), but the anti-
body detecting assembled VP2 only gave staining in the cyto-
sol. These ﬁndings suggest that nuclear transport of VP2 in
the assembled form was hampered in the absence of other viral
components that would be present in a normal infection. This
is in contrast with the results of Yuan and colleagues [8], who
showed singly expressed VP2 to accumulate in the nucleus of
A72 cells when probed with anti-capsid and anti-VP antibodies
at 48 h post-transfection. Use of diﬀerent cell lines could ex-
plain this discrepancy. In the case of minute virus of mice
(MVM), it has been suggested that VP2 enters the nucleus as
a trimeric complex with VP1 [18,19]. In our study, the assem-
bled VP2 remaining in the cytoplasm is consistent with the
inaccessibility of a nuclear transport motif mapped in the inter-
nal capsid surface for MVM.
There are a number of possibilities that could contribute to
the diﬀerent intracellular distribution of VP1 and assembled
VP2. Rapid accumulation of VP2 in the cytoplasm or binding
to intracellular structures could inhibit entry into the nucleus.
In support of this possibility, it has been shown that wt CPV
has the capacity to bind to lipids [14]. Alternatively, VP2 could
lack eﬀective nuclear translocation signals. This is probably
not the case, since non-assembled VP2 or VP2 in the presence
of other viral genes and viral non-structural proteins has been
shown to enter the nucleus [8,70]. We think the most probable
explanation to be that interaction of VP2 with VP1 is needed
to aid targeting of assembled VP2 into the nucleus. In fact,
interaction of structural proteins to aid in nuclear transloca-
tion has been previously shown for other viruses [71–73].
The co-transduction experiments (Fig. 5) conﬁrm that there
is a cooperation of VP1 aiding VP2 into the nucleus.
To ﬁnally conﬁrm the hypothesis that VP1 is necessary for
eﬃcient nuclear targeting of VP2, NLFK cells were transduced
with a recombinant baculovirus harboring VP2 fused to the N-
terminus of EGFP (Fig. 1). The transduced cells were then in-
fected with wild-type CPV and studied by direct viewing of the
ﬂuorescent VP2-EGFP fusion protein as well as by immunola-
beling of assembled VP2 (Fig. 6). The VP2-EGFP fusion pro-
tein was not able to eﬃciently enter the nucleus (Fig. 3) and
thus behaved in a similar way as VP2 alone (Fig. 3). However,
Fig. 6. Confocal imaging of NLFK cells transduced and infected with AcCMVVP2EGFP and authentic CPV, respectively (see Section 2). Nuclear
accumulation of the authentic and recombinant viral proteins was visualized with anti-VP (a), anti-VP1 (i) and anti-capsid (j) antibodies or by direct
viewing of the VP2EGFP fusion protein (c and k). DIC (d and i) and merged (h and p) images are shown to display the nucleus and colocalization of
the labeled proteins, respectively. Cells were also stained with anti-NS1 (b) against the non-structural protein 1 to conﬁrm CPV infection. Confocal
images are 0.7 lm thick midsections of the cell in the same ﬁeld. Bars 10 lm. The subcellular distributions of viral proteins (e), NS1 (f), the VP2EGFP
fusion protein (g and o), VP1 (m), and the capsid-like structures (n) are shown as an average percentage (n > 150) from two independent experiments.
Cells were classiﬁed into three categories as described in the legend to Fig. 2.
390 L. Gilbert et al. / FEBS Letters 579 (2005) 385–392when the transduced cells were infected with CPV, a clear nu-
clear accumulation of the VP2-EGFP fusion protein was ob-
served (Fig. 6). These results suggest that VP2 needs its
structural partner VP1 and/or other components of a wt infec-
tion in order to be eﬃciently targeted to the nucleus.
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